• Rapid adoption of CT:VQ™ by five leading U.S. academic medical centres within five months of FDA clearance
• Major expansion of distribution agreement with Philips, including minimum contractual order commitment of A$15 million over two years
• Health Canada regulatory approval obtained for CT:VQ™, unlocking a significant market

4DMedical Limited, a global leader in respiratory imaging technology, has reported a transformational quarter for the commercialisation of its CT:VQ™ technology. Within five months of FDA clearance, CT:VQ™ has been adopted by five of the most influential academic medical centres in the U.S., including Stanford, Cleveland Clinic, UC San Diego Health, University of Miami, and University of Chicago Medicine. This rapid adoption demonstrates the compelling clinical value of the technology and the effectiveness of 4DMedical's commercialisation strategy. The company also announced a significant expansion of its existing distribution agreement with Philips, which will see Philips distribute CT:VQ™ to healthcare systems across the United States and Canada on full commercial terms, with a minimum order commitment of approximately A$15 million over two years. Additionally, 4DMedical obtained regulatory approval for CT:VQ™ from Health Canada, unlocking a substantial market opportunity in Canada. The company also reported strong operational and financial performance, with underlying SaaS revenue growth of 31% in H1 FY26 and a proforma cash balance of $206.2 million following a successful $150 million institutional placement. With these milestones, 4DMedical is well-positioned to aggressively scale the commercialisation of CT:VQ™ and maintain a clear path to profitability.

4DMedical expects to generate a minimum contractual order commitment of approximately A$15 million (US$10 million) from Philips over the next two calendar years for the distribution of CT:VQ™ across healthcare systems in the United States and Canada.

4DMedical is entering 2026 with unprecedented momentum across all fronts, including a revolutionary technology with proven clinical adoption, strategic partnerships including Philips, regulatory approvals across North America, and a strong balance sheet to execute its growth strategy without distraction.